TITLE

Alimentary Health Enters Partnership With Norgine

PUB. DATE
October 2011
SOURCE
Worldwide Biotech;Oct2011, Vol. 23 Issue 10, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the partnership formed between specialty biotechnology firm Alimentary Health Limited (AH) and Norgine, a leading European specialty pharmaceutical firm. There is a plan by both AH and Norgine to collaborate on the evaluation of certain AH proprietary probiotic technology. Under the terms of the agreement, Norgine faces an option to negotiate a licence for the commercialisation of the technology.
ACCESSION #
66331187

 

Related Articles

  • Other News To Note.  // BioWorld International;1/25/2012, Vol. 17 Issue 4, p3 

    This section offers news briefs from the pharmaceutical biotechnology industry. A Phase I combination trial is being considered by Active Biotech AB of Sweden for the study of tasquinimod in prostate cancer. It relates the exclusive licensing agreement signed by Applied Pharma Research SA of...

  • Other News To Note.  // BioWorld Today;1/25/2012, Vol. 23 Issue 16, p4 

    This section offers news briefs on the biotechnology industry. Active Biotech AB is planning to conduct a Phase I trial to examine tasquinimod (TASQ) in prostate cancer. A licensing agreement has been signed between Applied Pharma Research SA, Labtech GmbH and Norgine BV. Regnite (gabapentin...

  • Tranzyme, Norgine in $158M Deal for Ghrelin Agonist.  // BioWorld Today;6/17/2010, Vol. 21 Issue 116, p5 

    The article reports on the agreement between Tranzyme Pharma Inc. and Norgine BV for the development and commercialization of ghrelin agonist, ulimorelin (TZP-101). The drug is being tested for its efficacy against post-operative ileus (POI). Other companies in the biotechnology industry have...

  • ICC Lowe. Iskowitz, Marc // Medical Marketing & Media;Jul2013, Vol. 48 Issue 7, p106 

    The article reports on digital integration model of North American healthcare agency ICC Lowe which is used to pave way for the future. It cites the rebranding of the company in 2011 boosting under the moniker of Interpublic Group's Lowe & Partners which landed to 15 accounts. It also notes the...

  • OTHER NEWS TO NOTE.  // BioWorld International;5/23/2007, Vol. 12 Issue 21, p2 

    The article presents news briefs on the European biotechnology industry. The two studies of Alimentary Health demonstrated the anti-inflammatory activity of Bifantis, a natural probiotic bacterial strain of human origin. An initial public offering is planned by Amsterdam Molecular Therapeutics...

  • The Biotech Licensing Challenge. Lachman, Ranan // Drug Discovery & Development;Oct2004, Vol. 7 Issue 10, p13 

    Discusses the changes being faced by biotechnology licensing in the United States. Increasing role played by licensing in the business model of pharmaceutical and biotechnology companies; Conditions limiting successful execution of in-licensing strategy; Issues that biotechnology companies must...

  • IRISH GASTROENTEROLOGY RESEARCHERS PIONEER IBS TREATMENTS.  // Worldwide Biotech;Jun2009, Vol. 21 Issue 6, p1 

    The article presents an update on drug development for irritable bowel syndrome (IBS) in Ireland as of June 2009. About 15 to 20 percent of all adolescents and adults in Western populations reportedly suffered from IBS. As reported, Alimentary Health has successfully commercialized innovations...

  • Patented Knowledge And Its Commercialization. Eui Kyo Jeong // International Journal of Contents;Jun2013, Vol. 9 Issue 2, p38 

    We examine whether the attributes of patented knowledge have any impact on its chances of commercialization. It has been hypothesized that the scope and cumulativeness of patented knowledge would positively affect the likelihood of its commercialization. The hypotheses were tested using patents...

  • Tranzyme, Norgine Dosing in Phase III Ulimorelin Studies.  // Bioworld Week;2/28/2011, Vol. 19 Issue 9, p3 

    The article offers information on the studies conducted by Tranzyme Pharma Inc. and Norgine BV which will assess the capacity and safety of dosage regimens of ulimorelin in accelerating gastrointestinal (GI) recovery of partial bowel resection patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics